Under the deal, Incyte will provide financial support for Vanderbilt’s grant-based research program, which has an initial collaboration period of three years, with the option to extend.
The collaboration will develop an improved understanding of basic cancer biology and the mechanisms of action of certain Incyte-proprietary compounds, as well as identify and develop new approaches to patient selection which may allow new therapeutic opportunities in oncology.
VICC/VUMC Hematology Early Therapy Program director Michael Savona said: "The Incyte pipeline of targeted therapies represents an opportunity for researchers here at Vanderbilt to test important hypotheses in a scientifically-aligned mission.
"We envision a collaboration centered on advancing our mechanistic understanding of cancer therapies."
Incyte chief scientific officer Reid Huber said: "Incyte and the Vanderbilt University Medical Center share a common goal of advancing innovative science to improve patients’ lives, and this alliance reflects this shared vision and the importance of collaborative research to achieve this end."